Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 8;43(9):1637-1655.e9.
doi: 10.1016/j.ccell.2025.06.019. Epub 2025 Jul 17.

A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture

Affiliations

A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture

Lasse Meyer et al. Cancer Cell. .

Abstract

Rapid recurrence is common in triple-negative breast cancer (TNBC). To better understand drivers of recurrence, we use imaging mass cytometry to characterize the tumor phenotype landscapes of 215 TNBC patients. We observe high intertumor heterogeneity with eleven tumor cell phenotypes, each of which dominates in an individual patient, and identify a tumor cell phenotype with reduced basoluminal lineage fidelity and stem-like traits that is correlated with rapid disease recurrence. Scoring of tumor-CD8+ T cell interactions identifies patients with inflamed tumors and high HLADR expression. We combine these features in multi-omics analyses of 8 cohorts with 3737 patients across all molecular subtypes to propose five prognostic breast cancer subtypes distinguished by tumor cytokeratin expression profiles and CD8+ T cell spatial patterns. This stratification scheme has direct clinical implications: inflamed tumors show good prognosis and high immunotherapy response rates, whereas patients dominated by basoluminal tumor cells have poor prognosis.

Keywords: breast cancer; disease recurrence; imaging mass cytometry; immunotherapy; multiplexed imaging; patient stratification; spatial single-cell atlas; triple-negative breast cancer; tumor phenotypes.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests B.B. co-founded and is a shareholder and member of the board of Navignostics, a precision oncology spin-off company from the University of Zurich. B.B. is a member of the scientific advisory board of Standard BioTools. All other authors declare no competing interests.

MeSH terms